Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

Plain-language guide to PMID 26445112 (2015): double-blind randomized controlled trial study of Glucagon and Oxyntomodulin.

Key Facts

PMID: 26445112
Journal: The Journal of clinical endocrinology and metabolism
Year: 2015
Study type: Randomized Controlled Trial
Authors: Bagger JI et al. (6 authors)
DOI: 10.1210/jc.2015-2335

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Glucagon and Oxyntomodulin, published as a randomized controlled trial.

The gut hormone, oxyntomodulin, is a proglucagon product with body weight-lowering potential.

It binds to both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor; however, the mechanism behind the body weight-lowering effect remains elusive.

Who Took Part

By PubMed's age tags, the people studied were teenagers, young adults and adults, men only.

Fifteen young healthy male volunteers (aged 22 [range 18-32] y; body mass index 23 [21-26] kg/m(2); fasting plasma glucose 5.1 [4.4-5.4] mmol/L; and glycated hemoglobin A1c 40 (37-42) mmol/mol).

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Glucagon.

Each person switched between Glucagon and the comparison at some point, usually with a gap in between.

This was a double-blinded, randomized, crossover study.

The study was conducted at a specialized research unit.

What Was Measured

Topics PubMed links to this paper include Acetaminophen, Analgesics, Non-Narcotic, Appetite, Drug Interactions, Eating, Energy Metabolism and Gastric Emptying.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Glucagon and Oxyntomodulin.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Glucagon compound page and the Oxyntomodulin compound page, all human trials.

Our Notes on the Compounds

Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.

Oxyntomodulin: A natural 37-amino-acid gut hormone that activates both GLP-1 and glucagon receptors; the model for the newer GLP-1/glucagon dual agonists.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.